NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas
Brian D Weiss, Pamela L Wolters, Scott R Plotkin, Brigitte C Widemann, James H Tonsgard, Jaishri Blakeley, Jeffrey C Allen, Elizabeth Schorry, Bruce Korf, Nathan J Robison, Stewart Goldman, Alexander A Vinks, Chie Emoto, Tsuyoshi Fukuda, Coretta T Robinson, Gary Cutter, Lloyd Edwards, Eva Dombi, Nancy Ratner, Roger Packer, Michael J Fisher, Brian D Weiss, Pamela L Wolters, Scott R Plotkin, Brigitte C Widemann, James H Tonsgard, Jaishri Blakeley, Jeffrey C Allen, Elizabeth Schorry, Bruce Korf, Nathan J Robison, Stewart Goldman, Alexander A Vinks, Chie Emoto, Tsuyoshi Fukuda, Coretta T Robinson, Gary Cutter, Lloyd Edwards, Eva Dombi, Nancy Ratner, Roger Packer, Michael J Fisher
Abstract
Purpose: Patients with neurofibromatosis type 1 (NF1) frequently develop plexiform neurofibromas (PNs), which can cause significant morbidity. We performed a phase II trial of the MAPK/ERK kinase inhibitor, mirdametinib (PD-0325901), in patients with NF1 and inoperable PNs. The primary objective was response rate based on volumetric magnetic resonance imaging analysis.
Methods: Inclusion criteria included age ≥ 16 years and a PN that was either progressive or causing significant morbidity. First-dose pharmacokinetics were performed. Patients completed patient-reported outcome measures. Patients received mirdametinib by mouth twice a day at 2 mg/m2/dose (maximum dose = 4 mg twice a day) in a 3-week on/1-week off sequence. Each course was 4 weeks in duration. Evaluations were performed after four courses for the first year and then after every six courses. Patients could receive a maximum of 24 total courses.
Results: Nineteen patients were enrolled, and all 19 received mirdametinib. The median age was 24 years (range, 16-39 years); the median baseline tumor volume was 363.8 mL (range, 3.9-5,161 mL). Eight of the 19 patients (42%) achieved a partial response of the target PN by course 12, and 10 (53%) had stable disease. One patient (5%) developed progressive disease at course 8. Significant and durable decreases were observed in pain ratings.
Conclusion: To our knowledge, this analysis represents the first characterization of the activity and pharmacokinetics of mirdametinib in patients with NF1 and PNs and is the first published response study for MAPK/ERK kinase inhibitors in adults with NF1 and PNs. Mirdametinib given at 2 mg/m2/dose (maximum dose, 4 mg) twice daily in a 3-week on/1-week off sequence resulted in a 42% partial response rate with preliminary evidence of reduction in pain.
Trial registration: ClinicalTrials.gov NCT02096471.
Figures
References
- Monroe CL, Dahiya S, Gutmann DH: Dissecting clinical heterogeneity in neurofibromatosis type 1. Annu Rev Pathol 12:53-74, 2017
- Wolters PL Burns KM Martin S, et al. : Pain interference in youth with neurofibromatosis type 1 and plexiform neurofibromas and relation to disease severity, social-emotional functioning, and quality of life. Am J Med Genet A 167A:2103-2113, 2015
- Dombi E Baldwin A Marcus LJ, et al. : Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. N Engl J Med 375:2550-2560, 2016
- Gross AM Wolters PL Dombi E, et al. : Selumetinib in children with inoperable plexiform neurofibromas. N Engl J Med 382:1430-1442, 2020
- Santarpia L, Lippman SM, El-Naggar AK: Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets 16:103-119, 2012
- Jousma E Rizvi TA Wu J, et al. : Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of Neurofibromatosis type 1. Pediatr Blood Cancer 62:1709-1716, 2015
- Boasberg PD Redfern CH Daniels GA, et al. : Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer. Cancer Chemother Pharmacol 68:547-552, 2011
- LoRusso PM Krishnamurthi SS Rinehart JJ, et al. : Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res 16:1924-1937, 2010
- Dombi E Solomon J Gillespie AJ, et al. : NF1 plexiform neurofibroma growth rate by volumetric MRI: Relationship to age and body weight. Neurology 68:643-647, 2007
- Downie WW Leatham PA Rhind VM, et al. : Studies with pain rating scales. Ann Rheum Dis 37:378-381, 1978
- Wolters PL Martin S Merker VL, et al. : Patient-reported outcomes of pain and physical functioning in neurofibromatosis clinical trials. Neurology 87:S4-S12, 2016
- Cleeland CS, Ryan KM: Pain assessment: Global use of the Brief Pain Inventory. Ann Acad Med Singapore 23:129-138, 1994
- Nutakki K Hingtgen CM Monahan P, et al. : Development of the adult PedsQL neurofibromatosis type 1 module: Initial feasibility, reliability and validity. Health Qual Life Outcomes 11:21, 2013
- Farrar JT Portenoy RK Berlin JA, et al. : Defining the clinically important difference in pain outcome measures. Pain 88:287-294, 2000
- Calvo M Zhu N Grist J, et al. : Following nerve injury neuregulin-1 drives microglial proliferation and neuropathic pain via the MEK/ERK pathway. Glia 59:554-568, 2011
- Zhuang ZY Gerner P Woolf CJ, et al. : ERK is sequentially activated in neurons, microglia, and astrocytes by spinal nerve ligation and contributes to mechanical allodynia in this neuropathic pain model. Pain 114:149-159, 2005
- Ji RR Befort K Brenner GJ, et al. : ERK MAP kinase activation in superficial spinal cord neurons induces prodynorphin and NK-1 upregulation and contributes to persistent inflammatory pain hypersensitivity. J Neurosci 22:478-485, 2002
- Shilyansky C, Lee YS, Silva AJ: Molecular and cellular mechanisms of learning disabilities: A focus on NF1. Annu Rev Neurosci 33:221-243, 2010
- de Gooijer MC Zhang P Weijer R, et al. : The impact of P-glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors. Int J Cancer 142:381-391, 2018
- Cui Y Costa RM Murphy GG, et al. : Neurofibromin regulation of ERK signaling modulates GABA release and learning. Cell 135:549-560, 2008
Source: PubMed